NCT03588936 is a Phase 1 clinical trial of Nivolumab (.25 mg/kg) in Acute Leukemia, sponsored by Medical College of Wisconsin.

Who is sponsoring NCT03588936?

NCT03588936 is sponsored by Medical College of Wisconsin.

What drugs are being tested in NCT03588936?

Interventions in NCT03588936: Nivolumab (.25 mg/kg), Tocilizumab, Nivolumab (.5 mg/kg).

What condition does NCT03588936 study?

NCT03588936 studies Acute Leukemia, Chronic Leukemia, Lymphoma, Myelodysplastic Syndromes.

Is NCT03588936 still recruiting?

NCT03588936 is currently terminated. Last updated 11 October 2021.

Last reviewed 2021-10-11 · How we verify

NCT03588936

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Terminated Phase 1 Last updated 11 October 2021

What this trial tests

Phase 1 trial testing Nivolumab (.25 mg/kg) in Acute Leukemia in 2 participants. Terminated before completion.

Timeline

14 September 2018

Primary endpoint
15 July 2020

15 July 2020

Quick facts

Lead sponsor	Medical College of Wisconsin
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	14 September 2018
Primary completion	15 July 2020
Estimated completion	15 July 2020
Sites	1 location across United States

Drugs / interventions tested

Nivolumab (.25 mg/kg) — full drug profile →
Tocilizumab (tocilizumab) — full drug profile →
Nivolumab (.5 mg/kg) — full drug profile →

Conditions studied

Acute Leukemia — all drugs for Acute Leukemia →
Chronic Leukemia — all drugs for Chronic Leukemia →
Lymphoma — all drugs for Lymphoma →
Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →

Sponsor

Medical College of Wisconsin

Who can join

18 and older, any sex, with Acute Leukemia or Chronic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1, interventional single arm, open label, treatment study designed to evaluate the safety combination programmed cell death protein 1 (PD-1) and interleukin 6 (IL-6) inhibition in participants with relapsed disease post-allogeneic transplant.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy.
Hao Z, Li R, Wang Y, Li S, et al · · 2021 · cited 72× · PMID 34689842 · DOI 10.1186/s40364-021-00333-5
Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Shi W, Jin W, Xia L, Hu Y. · · 2020 · cited 15× · PMID 32837873 · DOI 10.1016/j.apsb.2020.06.012
The Role of Immune Checkpoints after Cellular Therapy.
Schmitz F, Wolf D, Holderried TAW. · · 2020 · cited 13× · PMID 32455836 · DOI 10.3390/ijms21103650
Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study.
Chen Y, Luo Y, Liu Y, Luo D, et al · · 2025 · cited 7× · PMID 39752010 · DOI 10.1007/s00262-024-03899-9
Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?
Rozmus J, Bhatt ST, Buxbaum NP, Cuvelier GDE, et al · · 2022 · cited 4× · PMID 35402356 · DOI 10.3389/fped.2022.796994

Verify or expand the search:

Other recruiting trials for Acute Leukemia

Currently open trials in the same condition.

NCT07270770 — BY002 IIT Study in R/R Acute Leukemia · Phase 1 · recruiting
NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
NCT07362095 — Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) · Phase 1, PHASE2 · recruiting
NCT07101497 — Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia · Phase 2 · recruiting
NCT06984536 — Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT · Phase 2 · recruiting

Other Medical College of Wisconsin trials

Trials by the same sponsor.

NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease · not yet recruiting
NCT06795360 — Weight Changes After Incretin-mimetics · NA · not yet recruiting
NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes · NA · not yet recruiting
NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM · Phase 1, PHASE2 · not yet recruiting
NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03588936 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
Last refreshed: 11 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03588936.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing